Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice-Reference-Cited by-同舟云学术

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice

Published:2010-05-05 Issue:2 Volume:67 Page:421-430
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Beumer Jan H.,Eiseman Julie L.,Gilbert Judith A.,Holleran Julianne L.,Yellow-Duke Archibong E.,Clausen Dana M.,D’Argenio David Z.,Ames Matthew M.,Hershberger Pamela A.,Parise Robert A.,Bai Lihua,Covey Joseph M.,Egorin Merrill J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-010-1337-6.pdf

Reference37 articles.

1. Akaike H (1979) A Bayesian extension of the minimal AIC procedures of autoregressive model fitting. Biometrika 66:237–242

2. Ashour OM, Naguib FN, el Kouni MH (1996) 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2′, 3′, 5′-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy. Biochem Pharmacol 51:1601–1611

3. Beumer JH, Eiseman JL, Parise RA, Florian JA Jr, Joseph E, D’Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ (2008) Plasma pharmacokinetics and oral bioavailability of 3, 4, 5, 6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemother Pharmacol 62:457–464

4. Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, Egorin MJ (2008) Modulation of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3, 4, 5, 6-tetrahydrouridine. Clin Cancer Res 14:3529–3535

5. Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ (2006) Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine in mice. Clin Cancer Res 12:7483–7491

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker;Cancer Chemotherapy and Pharmacology;2020-09-18

2. The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?;Molecular Therapy;2020-02

3. Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance;Cancer Drug Resistance;2020

4. Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs;Chemical Reviews;2016-11-23

5. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*;Leukemia & Lymphoma;2016-10-24